Ipsen S.A. (VIE:IPN)

Market Cap	11.23B +13.7%
Revenue (ttm)	3.76B +11.5%
Net Income	447.90M -32.4%
EPS	5.37 -32.3%
Shares Out	n/a
PE Ratio	25.08
Forward PE	11.49
Dividend	1.40 (1.02%)
Ex-Dividend Date	Jun 4, 2025

Volume	n/a
Average Volume	4
Open	136.90
Previous Close	138.20
Day's Range	136.90 - 137.40
52-Week Range	88.30 - 139.00
Beta	n/a
RSI	55.74
Earnings Date	Feb 12, 2026

About Ipsen

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i...

• Industry: Pharmaceutical Preparations
• Founded: 1929
• Employees: 5,358
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: IPN

Financial Performance

In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.